ClinicalTrials.gg
RecruitingNCT07228247Updated Sep 22, 2026

A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors

A Phase 1/2 interventional study of HMPL-A251 and HMPL-A251 in Solid Tumors, Adult, sponsored by Hutchmed. Recruiting at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Hutchmed · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.

Read the detailed description
  • To evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDE) of HMPL-A251 in participants with previously treated HER2+ solid tumors
  • To characterize the safety and preliminary efficacy of HMPL-A251 at RDEs to determine recommended dose(s) for phase 2 (RP2D) or phase 3 (RP3D) in participants with selected HER2-expressing solid tumors
02

Conditions studied

  • Solid Tumors, Adult
03

In context

Lead sponsor

Hutchmed is the lead sponsor of 51 studies on the registry; 12 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed unresectable advanced or disease.
  2. Have at least one per v1.1;
  3. ≥ 12 weeks;
  4. (ECOG) performance status (PS) of 0-1;
  5. Weight ≥ 35 kg;

Exclusion criteria

Exclusion Criteria:

  1. An established diagnosis of type I diabetes mellitus or uncontrolled type II diabetes mellitus.
  2. Use of strong inhibitors or strong inducers of cytochrome P450 3A4 enzyme (), and inhibitors of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) within 5 elimination half-lives or 2 weeks (whichever is longer) before the first dose of study drug;
  3. Toxicity from prior anti-tumor therapy has not recovered to Grade 1 or baseline prior to the first dose of study drug (except alopecia). Participants with chronic Grade 2 toxicities may be eligible after discussion between the investigator and Sponsor Medical Monitor (e.g., Grade 2 chemotherapy-induced neuropathy);
  4. Baseline blood amylase or lipase exceeds the normal range and are judged by the investigators to be ;
  5. Spinal cord compression, , or clinically active central nervous system (CNS) , defined as untreated or symptomatic, or requiring therapy with or anticonvulsants to control associated symptoms;
  6. Major surgery within 28 days prior to the first dose of study drug. Participants must have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study drug(s);
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
147 participants (estimated)

Study arms

  • Experimental
    Part A(Phase I)

    Dose Escalation

    Drug: HMPL-A251

  • Experimental
    Part B(Phase IIa)

    Dose Expansion/Dose Optimization

    Drug: HMPL-A251

Interventions

  • DrugHMPL-A251

    Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

  • DrugHMPL-A251

    Participants will be randomized in a 1:1 ratio to receive treatment in two RDEs levels (approximately 15 participants per dose level) for each cohort. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    At least three participants will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN) will be used to guide dose escalation and to determine the MTD of HMPL-A251

    Time frame: Approximately 12 months

  2. Recommended doses for expansion (RDE)

    The RDE will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data, such as chronic toxicities, discontinuations, or withdrawals for toxicity that occur beyond the DLT period; PK data collected at the time of evaluation; Preliminary efficacy data.

    Time frame: Approximately 12 months

  3. Overview of Treatment-emergent Adverse Events (TEAEs)

    All TEAEs will be graded according to NCI CTCAE v6.0 and coded using the Medical Dictionary for Regulatory Activities (MedDRA).

    Time frame: Approximately 24 months

  4. Objective Response Rate (ORR)

    ORR is defined as the proportion of participants with Best objective response (BOR) of confirmed complete response (CR) or partial response (PR), as per investigator's assessment according to RECIST v1.1.

    Time frame: At least 6 weeks post dose of first participant up to approximately 24 months

  5. Recommended doses for phase II or III studies (RP2D or RP3D) of HMPL-A251

    The RP2D or RP3D will be selected by evaluating all available data from the following criteria under consideration: Determination of MTD achieved during the dose escalation part; Safety data obtained across all different doses tested; Tolerability data; PK data; efficacy data.

    Time frame: Approximately 12 months

Secondary outcomes

  1. Disease control rate (DCR)

    The proportion of participants with BOR of confirmed CR, confirmed PR, or stable disease (SD) lasting at least 5 weeks.

    Time frame: Approximately 2 years

  2. Duration of response (DoR)

    Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first occurrence of objective tumor response (CR or PR) to the date of first radiographic PD or death due to any cause.

    Time frame: Approximately 2 years

  3. Time to response (TTR)

    Only applies to participants whose BOR is confirmed CR or PR and is defined as the time from the first dose of study dose to the first occurrence of objective tumor response (CR or PR)

    Time frame: Approximately 2 years

  4. Progression-free survival (PFS)

    The time from the first dose of study drug to the date of first radiographic PD per RECIST v1.1 or death due to any cause, whichever occurs first.

    Time frame: Approximately 2 years

  5. Overall survival (OS)

    Every 12 weeks (± 7 days) until death, withdrawal of consent for follow-up, lost to follow-up or end of study, whichever occurs first.

    Time frame: Approximately 2 years

  6. Maximum plasma/serum concentration (Cmax)

    Observed maximum plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609; only applies to Cycles 1 and 3.

    Time frame: Cycle 1 and Cycle 3 (21-day cycle)

  7. Time to maximum plasma/serum concentration (Tmax)

    Time to observed Cmax for HMPL-A251, total anti-HER2 antibody, and HM5041609

    Time frame: Cycle 1 and Cycle 3 (21-day cycle)

  8. Area under the plasma/serum concentration-time curve (AUC)

    Derived from the observed plasma/serum concentration-time data for HMPL-A251, total anti-HER2 antibody, and HM5041609 using noncompartmental analysis

    Time frame: Cycle 1 and Cycle 3 (21-day cycle)

  9. Pre-dose plasma/serum concentration (Cmin)

    Observed pre-dose plasma/serum concentration of HMPL-A251, total anti-HER2 antibody, and HM5041609.

    Time frame: Each cycle (21-day cycle); from C9, every 4 cycles, through approximately 12 months

  10. Immunogenicity of HMPL-A251

    Incidence of anti-drug antibody and neutralizing antibody against HMPL-A251

    Time frame: Each cycle (21-day cycle), From C9, every 4 cycles, Approximately 12 months

07

Study locations

11 of 15 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Nov 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2025
First posted
Nov 14, 2025
StartActual
Dec 16, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Dec 31, 2028
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07228247
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Nov 14, 2025
Start date
Dec 16, 2025
Primary completion
Nov 30, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Sep 22, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion